(BMY) Bristol-Myers Squibb - Overview
Stock: Oncology, Immunology, Hematology, Cardiovascular, Neurology
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.98% |
| Yield on Cost 5y | 5.04% |
| Yield CAGR 5y | 13.97% |
| Payout Consistency | 92.6% |
| Payout Ratio | 40.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 36.0% |
| Relative Tail Risk | -9.29% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.44 |
| Alpha | 1.25 |
| Character TTM | |
|---|---|
| Beta | 0.322 |
| Beta Downside | 0.369 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.43% |
| CAGR/Max DD | -0.01 |
Description: BMY Bristol-Myers Squibb January 27, 2026
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes prescription medicines across oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. Its flagship products include Eliquis (anticoagulant), Opdivo (PD-1 checkpoint inhibitor), Revlimid (multiple myeloma), and newer launches such as Krazati (KRAS G12C NSCLC) and Opdualag (melanoma).
In the most recent quarter (Q2 2024), BMY reported revenue of **$13.2 billion**, up **7 % YoY**, driven primarily by oncology sales (+9 %) and the continued growth of Eliquis (+5 %). Adjusted earnings per share were **$2.30**, and the company spent **$6.2 billion** on R&D, representing roughly **47 %** of net sales. As of the end of June 2024, BMY’s net debt stood at **$30 billion**, while its cash-equivalent balance was **$5.5 billion**, giving a net-debt-to-EBITDA ratio of about **2.3×**, indicating moderate leverage relative to peers.
Key macro- and sector-level drivers for BMY include: (1) an aging U.S. and global population that sustains demand for chronic-disease therapies such as anticoagulants and immunomodulators; (2) the oncology market’s projected **CAGR of ~6 % through 2030**, which benefits BMY’s expanding pipeline of checkpoint inhibitors and KRAS-targeted agents; and (3) pricing pressure from biosimilars and payer reforms, which could compress margins unless offset by higher-value specialty products. The company’s pipeline contains several late-stage candidates (e.g., a next-generation CAR-T therapy and a novel anti-fibrotic agent) that could diversify revenue streams but also introduce execution risk.
For a deeper, data-driven assessment of BMY’s valuation dynamics, consider exploring the detailed analyst models on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 7.05b TTM > 0 and > 6% of Revenue |
| FCF/TA: 1.43 > 0.02 and ΔFCF/TA 128.5 > 1.0 |
| NWC/Revenue: -36.23% < 20% (prev 12.43%; Δ -48.67% < -1%) |
| CFO/TA 1.56 > 3% & CFO 16.62b > Net Income 7.05b |
| Net Debt (-55.32b) to EBITDA (14.54b): -3.80 < 3 |
| Current Ratio: 0.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.04b) vs 12m ago 0.20% < -2% |
| Gross Margin: 67.65% > 18% (prev 0.57%; Δ 6708 % > 0.5%) |
| Asset Turnover: 93.33% > 50% (prev 52.16%; Δ 41.17% > 0%) |
| Interest Coverage Ratio: 7.08 > 6 (EBITDA TTM 14.54b / Interest Expense TTM 1.51b) |
Altman Z'' -3.37
| A: -1.64 (Total Current Assets 10.67b - Total Current Liabilities 28.14b) / Total Assets 10.67b |
| B: 1.60 (Retained Earnings 17.09b / Total Assets 10.67b) |
| C: 0.21 (EBIT TTM 10.69b / Avg Total Assets 51.64b) |
| D: 0.71 (Book Value of Equity 55.78b / Total Liabilities 78.29b) |
| Altman-Z'' Score: -3.37 = D |
What is the price of BMY shares?
Over the past week, the price has changed by +10.91%, over one month by +10.89%, over three months by +32.72% and over the past year by +17.27%.
Is BMY a buy, sell or hold?
- StrongBuy: 4
- Buy: 4
- Hold: 18
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the BMY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 58.8 | -5.2% |
| Analysts Target Price | 58.8 | -5.2% |
| ValueRay Target Price | 70.7 | 14.1% |
BMY Fundamental Data Overview February 08, 2026
P/E Forward = 9.9701
P/S = 2.6185
P/B = 5.3387
P/EG = 2.2562
Revenue TTM = 48.19b USD
EBIT TTM = 10.69b USD
EBITDA TTM = 14.54b USD
Long Term Debt = 44.47b USD (from longTermDebt, two quarters ago)
Short Term Debt = 4.94b USD (from shortTermDebt, two quarters ago)
Debt = 51.04b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -55.32b USD (from netDebt column, last quarter)
Enterprise Value = 166.56b USD (126.20b + Debt 51.04b - CCE 10.67b)
Interest Coverage Ratio = 7.08 (Ebit TTM 10.69b / Interest Expense TTM 1.51b)
EV/FCF = 10.89x (Enterprise Value 166.56b / FCF TTM 15.30b)
FCF Yield = 9.19% (FCF TTM 15.30b / Enterprise Value 166.56b)
FCF Margin = 31.75% (FCF TTM 15.30b / Revenue TTM 48.19b)
Net Margin = 14.63% (Net Income TTM 7.05b / Revenue TTM 48.19b)
Gross Margin = 67.65% ((Revenue TTM 48.19b - Cost of Revenue TTM 15.59b) / Revenue TTM)
Gross Margin QoQ = 67.23% (prev 71.89%)
Tobins Q-Ratio = 15.61 (Enterprise Value 166.56b / Total Assets 10.67b)
Interest Expense / Debt = 0.10% (Interest Expense 51.0m / Debt 51.04b)
Taxrate = 26.12% (384.0m / 1.47b)
NOPAT = 7.89b (EBIT 10.69b * (1 - 26.12%))
Current Ratio = 0.38 (Total Current Assets 10.67b / Total Current Liabilities 28.14b)
Debt / Equity = 0.91 (Debt 51.04b / totalStockholderEquity, last quarter 55.78b)
Debt / EBITDA = -3.80 (Net Debt -55.32b / EBITDA 14.54b)
Debt / FCF = -3.62 (Net Debt -55.32b / FCF TTM 15.30b)
Total Stockholder Equity = 27.29b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.66% (Net Income 7.05b / Total Assets 10.67b)
RoE = 25.84% (Net Income TTM 7.05b / Total Stockholder Equity 27.29b)
RoCE = 14.89% (EBIT 10.69b / Capital Employed (Equity 27.29b + L.T.Debt 44.47b))
RoIC = 11.77% (NOPAT 7.89b / Invested Capital 67.08b)
WACC = 5.08% (E(126.20b)/V(177.24b) * Re(7.10%) + D(51.04b)/V(177.24b) * Rd(0.10%) * (1-Tc(0.26)))
Discount Rate = 7.10% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.20%
[DCF Debug] Terminal Value 87.00% ; FCFF base≈14.70b ; Y1≈15.76b ; Y5≈19.16b
Fair Price DCF = 305.8 (EV 567.21b - Net Debt -55.32b = Equity 622.53b / Shares 2.04b; r=5.90% [WACC]; 5y FCF grow 8.04% → 2.90% )
EPS Correlation: -12.32 | EPS CAGR: -12.29% | SUE: -1.59 | # QB: 0
Revenue Correlation: 59.09 | Revenue CAGR: 1.90% | SUE: 1.02 | # QB: 9
EPS next Quarter (2026-03-31): EPS=1.40 | Chg30d=-0.035 | Revisions Net=+1 | Analysts=8
EPS current Year (2026-12-31): EPS=6.24 | Chg30d=+0.213 | Revisions Net=+3 | Growth EPS=+1.4% | Growth Revenue=-4.1%
EPS next Year (2027-12-31): EPS=5.96 | Chg30d=+0.112 | Revisions Net=+1 | Growth EPS=-4.4% | Growth Revenue=-5.2%